Exhibit 99.1 Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data REDWOOD CITY, Calif. February 29, 2024 – Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights "In 2023, our customers cont ...

Seer, Inc. (NASDAQ:SEER) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Omid Farokhzad - President, CEO David Horn - CFO Conference Call Participants Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Marta Nazarovets - JP Morgan Operator Good day, and thank you for standing by. Welcome to the Seer Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a qu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Delaware 82-1153150 (I.R.S. Employer Identification Number) 3800 Bridge Parkway, Suite 102 Redwood City, California ...

Seer, Inc. (NASDAQ:SEER) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Omid Farokhzad - Chief Executive Officer, President & Chair David Horn - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Derek De Bruin - Bank of America Kyle Boucher - TD Cowen Operator Good day, and thank you for standing by. Welcome to the Seer, Inc. Second Quarter 2023 Earnings Conference Call. At this time, all participants are ...

FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-39747 SEER, INC. (Exact name of Registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (State or other juris ...

Seer, Inc. (NASDAQ:SEER) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Omid Farokhzad - CEO, President and Chair David Horn - CFO Conference Call Participants Gabby Shaw - Morgan Stanley Kyle Boucher - TD Cowen Operator Good day. And thank you for standing by. Welcome to the Seer First Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised today's conference is being recorded. I would like to hand the conference over to your speake ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-39747 SEER, INC. (Exact name of Registrant as specified in its charter) (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-39747 SEER, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdict ...

Seer, Inc. (NASDAQ:SEER) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Carrie Mendivil – Investor Relations Omid Farokhzad – Chair, President and Chief Executive Officer David Horn – Chief Financial Officer Conference Call Participants Derik De Bruin – Bank of America Kyle Boucher – Cowen Tejas Savant – Morgan Stanley Operator Thank you for standing by and welcome to the Seer Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2022 was $4 million, an increase of 84% compared to $2.2 million in Q3 2021, primarily due to increased sales of the Proteograph Product Suite [43][44] - Total gross profit was $1.9 million for Q3 2022, representing a gross margin of 49%, which improved sequentially due to higher consumable sales [45] - Net loss for Q3 2022 was $24 million, compared to $18.4 million in Q3 2021 [49] Business Line Data and Key Metrics Changes - Product revenue for Q3 2022 was $3.9 million, including related party revenue of $1.3 million from sales of SP100 instruments, consumable kits, and platform evaluations [44] - Research and development expenses for Q3 2022 were $11.6 million, an increase of 49% compared to $7.7 million in Q3 2021, driven by increased product development efforts related to the Proteograph Product Suite [47] - Selling, general, and administrative expenses for Q3 2022 were $15.4 million, an increase of 30% compared to $11.9 million in Q3 2021 [48] Market Data and Key Metrics Changes - The company is seeing strong interest across geographies, with a pipeline of qualified leads split equally between academic and commercial customers [30] - The macroeconomic environment is impacting biopharma spending, with constrained CapEx budgets and elongated purchasing decisions noted in various markets, including China and Europe [32][84] Company Strategy and Development Direction - The company aims to support customers in scaling their use of the Proteograph Product Suite, expand its global customer network, and enhance partnerships to facilitate technology adoption [15] - The strategic focus includes driving a product roadmap to enable more applications and increasing the resolution of proteomic studies through initiatives like the Human Proteome Project [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the growing enthusiasm for the Proteograph Product Suite and its potential to enable population-scale studies [8][41] - The company expects revenue for 2022 to be in the range of $14 million to $16 million, with enthusiasm for technology expected to drive revenues towards the upper half of this range despite macroeconomic challenges [50] Other Important Information - The company ended Q3 2022 with approximately $441 million in cash, cash equivalents, and investments, indicating a strong balance sheet to support strategic plans [49] - The company has renewed its SBIR grant from the NIH, expecting a resumption of revenue contributions from grant and research-related collaborations starting in Q4 2022 [44] Q&A Session Summary Question: Can you discuss the funnel and guidance for the full year? - Management noted significant interest from proteomics and genomics researchers, with a pipeline split 50/50 between commercial and academic customers, but elongated purchasing decisions due to macroeconomic factors [56][60] Question: What notable publications or studies should be expected? - Management highlighted that several manuscripts are expected to be submitted by the end of 2022 and into 2023, with a focus on high-impact studies demonstrating the capabilities of the Proteograph [64][67] Question: How should spending patterns be viewed for next year? - Management emphasized a prudent approach to spending, with a focus on maintaining free cash flow and being mindful of capital deployment [75][76] Question: Are larger scale proteomics studies expected to contribute meaningfully in 2023? - Management indicated visibility for multi-thousand sample studies in 2023 but not for studies involving tens of thousands of samples yet [78] Question: How do purchasing cycles differ by geography? - Management noted that purchasing decisions are elongated globally, with specific challenges in China and Europe due to economic conditions [84][86] Question: What is the outlook for the Proteogenomics Consortium? - Management expressed optimism about the partnership's potential to scale, with strong interest from genomics customers seeking access to data [90] Question: Can you elaborate on gross margin improvements? - Management attributed the increase in gross margin to higher consumable sales and discussed potential improvements in instrument and kit gross margins over time [94][96] Question: What is the scope of revenue from research customers? - Management clarified that grant revenue from the NIH will resume in Q4, historically ranging from tens of thousands to low hundreds of thousands per quarter [100] Question: Are there plans to work with liquid biopsy companies? - Management confirmed ongoing discussions with various companies to integrate proteomics into genomic analysis workflows [102]